Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Ayala Pharmaceuticals

Ayala Pharmaceuticals Files Form 15 to Voluntarily Deregister and Suspend its Reporting Obligations
From Ayala Pharmaceuticals
Via GlobeNewswire
Tickers ADXS
Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome
From Ayala Pharmaceuticals
Via GlobeNewswire
Tickers ADXS IMNM
Ayala Pharmaceuticals Announces Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors
From Ayala Pharmaceuticals
Via GlobeNewswire
Tickers ADXS IMNM
Immunome To Acquire AL102, A Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals
From Ayala Pharmaceuticals
Via GlobeNewswire
Tickers ADXS IMNM
Ayala Pharmaceuticals Announces AL102 Receives Orphan Drug Designation for Desmoid Tumors
From Ayala Pharmaceuticals
Via GlobeNewswire
Tickers ADXS
Ayala Pharmaceuticals Presents Updated AL102 Results from Phase 2 Clinical Trial in Desmoid Tumors at ESMO Congress 2023
From Ayala Pharmaceuticals
Via GlobeNewswire
Tickers ADXS
Ayala Pharmaceuticals Announces Closing of Merger with Biosight
From Ayala Pharmaceuticals
Via GlobeNewswire
Tickers ADXS
Ayala Pharmaceuticals Announces Second Quarter 2023 Financial Results and Provides Corporate Update
From Ayala Pharmaceuticals
Via GlobeNewswire
Tickers ADXS
Ayala Pharmaceuticals Announces Abstracts on AL102 and AL101 Accepted for Presentation at ESMO Congress 2023
From Ayala Pharmaceuticals
Via GlobeNewswire
Tickers ADXS
Ayala Pharmaceuticals and Biosight Enter into Definitive Merger Agreement
From Ayala Pharmaceuticals
Via GlobeNewswire
Tickers ADXS
Ayala Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA Regarding AL102 for the Treatment of Desmoid Tumors
From Ayala Pharmaceuticals
Via GlobeNewswire
Tickers ADXS
Updated RINGSIDE Phase 2 Results Featured in Poster Discussion Session at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
From Ayala Pharmaceuticals
Via GlobeNewswire
Tickers ADXS
Ayala Pharmaceuticals Announces Updated RINGSIDE Phase 2 Results at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
From Ayala Pharmaceuticals
Via GlobeNewswire
Tickers ADXS
Ayala Pharmaceuticals Announces First Quarter 2023 Financial Results and Provides Corporate Update
From Ayala Pharmaceuticals
Via GlobeNewswire
Tickers ADXS
Ayala Pharmaceuticals Announces RINGSIDE Results to be Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
From Ayala Pharmaceuticals
Via GlobeNewswire
Tickers ADXS
Ayala Pharmaceuticals Announces Continuation of RINGSIDE Phase 2/3 Study in Desmoid Tumors Following Recommendation of Independent Data Monitoring Committee
From Ayala Pharmaceuticals
Via GlobeNewswire
Tickers ADXS
Ayala Pharmaceuticals Reports Financial Results For the Fiscal Year Ended October 31, 2022
From Ayala Pharmaceuticals
Via GlobeNewswire
Tickers ADXS
Ayala Pharmaceuticals Presents Poster on AL102 in Desmoid Tumors at the Connective Tissue Oncology Society (CTOS) 2022 Annual Meeting
From Ayala Pharmaceuticals
Via GlobeNewswire
Tickers AYLA
Ayala Pharmaceuticals Announces First Patient Dosed with AL102 in Phase 3 Segment of RINGSIDE Trial in Desmoid Tumors
From Ayala Pharmaceuticals
Via GlobeNewswire
Tickers AYLA
Ayala Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
From Ayala Pharmaceuticals
Via GlobeNewswire
Tickers AYLA
Ayala Pharmaceuticals and Advaxis Enter into Merger Agreement
From Ayala Pharmaceuticals
Via GlobeNewswire
Tickers ADXS AYLA
Ayala Pharmaceuticals to Host Key Opinion Leader Webinar on Desmoid Tumors
From Ayala Pharmaceuticals
Via GlobeNewswire
Tickers AYLA
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.